Research programme: anticancer antibodies - Cellerant

Drug Profile

Research programme: anticancer antibodies - Cellerant

Alternative Names: anti-IL1RAP; CSC 17.7; CSC012-ADC; CSC030-ADC; CSC17.1

Latest Information Update: 13 Oct 2016

Price : $50

At a glance

  • Originator Cellerant Therapeutics
  • Class Drug conjugates; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; C-type lectin modulators; Immunomodulators; Interleukin-1 receptor accessory protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Solid tumours
  • Research Multiple myeloma; Myelodysplastic syndromes

Most Recent Events

  • 11 Oct 2016 Preclinical pharmacodynamics data in Acute myeloid leukaemia released by Cellerant Therapeutics
  • 26 Sep 2016 Preclinical trials in Solid tumours in USA (Parenteral)
  • 26 Sep 2016 Cellerant Therapeutics receives SBIR grant from National Cancer Institute for CSC012-ADC development in Acute myeloid leukaemia and Myelodysplastic syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top